To verify whether FHL3 promotes HCC progression through the KRAS signaling pathway, we knocked down KRAS on the basis of FHL3 overexpression in the Hep3B cell line and overexpressed KRAS on the basis of FHL3 knockdown in the MHCC97H cell line. The gene discussed is KRAS; the disease is hepatocellular carcinoma.